News | Heart Failure | June 24, 2015

Scott & White Memorial Uses CardioMEMS HF System to Help Heart Failure Patients

Hospital is sixth in Texas to adopt new remote monitoring device for heart failure

CardioMEMS, Scott & White Memorial, Texas, heart failure, remote monitoring

June 24, 2015 ­- Scott & White Memorial – Temple for the first time implanted a new miniaturized, wireless monitoring sensor to help manage heart failure (HF). Scott & White Memorial is one of six hospitals in Texas and the first hospital in the Baylor Scott & White Health system to offer the device.

"We are always looking for new and innovative ways to treat our patient's disease process and improve outcomes for heart failure patients," said Robert Scott III, M.D., director for advanced heart failure at Scott & White Memorial. "This device will give us the ability to anticipate problems with our patients before they occur, decreasing their chance of being re-admitted to the hospital, and improving their quality of life."

Memorial implemented the CardioMEMS HF System, a U.S. Food and Drug Administration (FDA)-approved heart failure monitoring device proven to significantly reduce hospital admissions.

The device is a sensor that is implanted in the pulmonary artery (PA) during a minimally invasive procedure. Once implanted, the device can measure and transmit PA pressure from the patient back to their healthcare team. Elevation in PA pressure appears even before changes in weight and blood pressure in the patient, which are traditionally used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their healthcare providers allowing for personalized and proactive management to reduce the likelihood of hospitalization and onset of debilitating symptoms.

"Heart failure can rob patients' quality of life and frequently results in repeated hospitalizations," said John Erwin III, M.D., cardiologist at Scott & White Memorial. "We think that we can provide significantly improved quality of life by partnering with the patient in acting preventatively as opposed to responding when an adverse event occurs."

For more information: www.sw.org

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Overlay Init